SHUKRAPHARPharmaceuticals
Shukra Pharmaceuticals Ltd — Profit & Loss Statement
₹30.34
-3.42%
Shukra Pharmaceuticals Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.00 | 0.00 | 42424.84 | 84548.72 | — |
| Tax Rate For Calcs | 0.28 | 0.07 | 0.01 | 0.26 | — |
| Normalized EBITDA | 16.94 Cr | 22.22 Cr | 6.10 Cr | 2.93 Cr | — |
| Total Unusual Items | 0.00 | 0.00 | 0.44 Cr | 0.03 Cr | — |
| Total Unusual Items Excluding Goodwill | 0.00 | 0.00 | 0.44 Cr | 0.03 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 9.58 Cr | 18.54 Cr | 4.41 Cr | 0.75 Cr | — |
| Reconciled Depreciation | 3.00 Cr | 2.05 Cr | 1.84 Cr | 1.66 Cr | — |
| Reconciled Cost Of Revenue | 8.11 Cr | 44.49 Cr | 45.32 Cr | 10.35 Cr | — |
| EBITDA | 16.94 Cr | 22.22 Cr | 6.53 Cr | 2.96 Cr | — |
| EBIT | 13.93 Cr | 20.17 Cr | 4.70 Cr | 1.30 Cr | — |
| Net Interest Income | -0.59 Cr | -0.28 Cr | -0.22 Cr | -0.26 Cr | — |
| Interest Expense | 0.59 Cr | 0.28 Cr | 0.26 Cr | 0.28 Cr | — |
| Normalized Income | 9.58 Cr | 18.54 Cr | 3.97 Cr | 0.73 Cr | — |
| Net Income From Continuing And Discontinued Operation | 9.58 Cr | 18.54 Cr | 4.41 Cr | 0.75 Cr | — |
| Total Expenses | 22.86 Cr | 57.22 Cr | 55.31 Cr | 19.26 Cr | — |
| Diluted NI Availto Com Stockholders | 9.58 Cr | 18.54 Cr | 4.41 Cr | 0.75 Cr | — |
| Net Income Common Stockholders | 9.58 Cr | 18.54 Cr | 4.41 Cr | 0.75 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 9.58 Cr | 18.54 Cr | 4.41 Cr | 0.75 Cr | — |
| Net Income Including Noncontrolling Interests | 9.58 Cr | 18.54 Cr | 4.41 Cr | 0.75 Cr | — |
| Net Income Continuous Operations | 9.58 Cr | 18.54 Cr | 4.41 Cr | 0.75 Cr | — |
| Tax Provision | 3.76 Cr | 1.35 Cr | 0.04 Cr | 0.27 Cr | — |
| Pretax Income | 13.34 Cr | 19.88 Cr | 4.44 Cr | 1.02 Cr | — |
| Other Non Operating Income Expenses | 4.21 Cr | 2.82 Cr | 0.70 Cr | 0.02 Cr | — |
| Special Income Charges | 0.00 | 0.00 | 0.44 Cr | 0.03 Cr | — |
| Net Non Operating Interest Income Expense | -0.59 Cr | -0.28 Cr | -0.22 Cr | -0.26 Cr | — |
| Interest Expense Non Operating | 0.59 Cr | 0.28 Cr | 0.26 Cr | 0.28 Cr | — |
| Operating Income | 9.72 Cr | 17.35 Cr | 3.53 Cr | 1.22 Cr | — |
| Operating Expense | 14.75 Cr | 12.73 Cr | 9.99 Cr | 8.92 Cr | — |
| Other Operating Expenses | 5.64 Cr | 5.04 Cr | 1.99 Cr | 1.11 Cr | — |
| Depreciation And Amortization In Income Statement | 3.00 Cr | 2.05 Cr | 1.84 Cr | 1.66 Cr | — |
| Depreciation Income Statement | 3.00 Cr | 2.05 Cr | 1.84 Cr | 1.66 Cr | — |
| Gross Profit | 24.48 Cr | 30.09 Cr | 13.52 Cr | 10.14 Cr | — |
| Cost Of Revenue | 8.11 Cr | 44.49 Cr | 45.32 Cr | 10.35 Cr | — |
| Total Revenue | 32.59 Cr | 74.57 Cr | 58.83 Cr | 20.49 Cr | — |
| Operating Revenue | 32.59 Cr | 74.57 Cr | 58.83 Cr | 20.49 Cr | — |
| Interest Income | — | 0.56 Cr | 0.06 Cr | 0.03 Cr | 0.05 Cr |
| Rent Expense Supplemental | — | 0.49 Cr | 0.54 Cr | 0.71 Cr | 0.53 Cr |
| Diluted Average Shares | — | 43.79 Cr | 6.73 Cr | 30.10 Cr | 30.10 Cr |
| Basic Average Shares | — | 43.79 Cr | 6.73 Cr | 30.10 Cr | 30.10 Cr |
| Diluted EPS | — | 4.23 | 0.66 | 0.02 | 0.01 |
| Basic EPS | — | 4.23 | 0.66 | 0.02 | 0.01 |
| Write Off | — | -0.25 Cr | -0.44 Cr | -0.03 Cr | 0.00 |
| Total Other Finance Cost | — | 87000.00 | 0.03 Cr | 53000.00 | 0.02 Cr |
| Interest Income Non Operating | — | 0.56 Cr | 0.06 Cr | 0.03 Cr | 0.05 Cr |
| Research And Development | — | 0.13 Cr | 0.12 Cr | 0.09 Cr | 0.05 Cr |
| Selling General And Administration | — | 2.80 Cr | 0.61 Cr | 0.44 Cr | 0.23 Cr |
| Selling And Marketing Expense | — | 2.12 Cr | 99000.00 | 90000.00 | 0.04 Cr |
| General And Administrative Expense | — | 0.67 Cr | 0.60 Cr | 0.43 Cr | 0.19 Cr |
| Rent And Landing Fees | — | 0.49 Cr | 0.54 Cr | 0.71 Cr | 0.53 Cr |
| Net Income Discontinuous Operations | — | — | — | — | 0.00 |
| Other Special Charges | — | — | — | — | 0.20 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Shukra Pharmaceuticals Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.